Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1

Conditions

Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Sarcoma 1Neoplasm Metastasis 1Nasopharyngeal Carcinoma 1Hodgkin Disease 1Esophageal Neoplasms 1Colonic Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Advanced Primary Liver Cancer 1

Interventions

Cisplatin 4pembrolizumab 3Nivolumab 3Fluorouracil 2Carboplatin 2toripalimab 1spartalizumab 1fludarabine phosphate 1fludarabine 1cc-486 1camrelizumab 1Vorinostat 1Valganciclovir 1Range of Motion, Articular 1Radiotherapy 1Radiosurgery 1Protons 1Platinum 1Methylprednisolone 1Medicare Part B 1Laryngoscopes 1Gemcitabine 1Docetaxel 1Cyclophosphamide 1Cetuximab 1Bevacizumab 1Azacitidine 1Adrenal Cortex Hormones 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Nasopharyngeal Carcinoma × camrelizumab × Clear all
NCT03558191 2024-03-15

SHR-1210 in Recurrent/Metastatic Nasopharyngeal Carcinoma Who Have Received Previous At Least Two Lines of Chemotherapy.

Jiangsu HengRui Medicine Co., Ltd.

Phase 2 Completed
156 enrolled 13 charts
Head & Neck

Nasopharyngeal Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡